Addex Therapeutics Ltd. Sponsored ADR (NASDAQ:ADXN) Short Interest Update

Addex Therapeutics Ltd. Sponsored ADR (NASDAQ:ADXN) saw a significant decline in short interest in June. As of June 15th, there was short interest totaling 1,344 shares, a decline of 73.0% from the May 31st total of 4,982 shares. Approximately 0.1% of the company’s stock are sold short. Based on an average trading volume of 4,313 shares, the short-interest ratio is currently 0.3 days.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Addex Therapeutics in a research report on Wednesday, April 8th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Addex Therapeutics presently has an average rating of “Sell”.

Addex Therapeutics Stock Performance

ADXN opened at $6.07 on Friday. The firm has a 50-day moving average of $6.66 and a 200 day moving average of $7.12. Addex Therapeutics has a fifty-two week low of $5.41 and a fifty-two week high of $12.05. The firm has a market cap of $7.47 million, a P/E ratio of -1.06 and a beta of 1.48.

Addex Therapeutics (NASDAQ:ADXN) last issued its earnings results on Thursday, June 25th. The company reported ($1.50) earnings per share (EPS) for the quarter. The business had revenue of $0.01 million during the quarter.

Addex Therapeutics Company Profile

Addex Therapeutics SA is a clinical-stage biopharmaceutical company specializing in the discovery and development of small-molecule allosteric modulators for central nervous system disorders. Founded in 1999 and headquartered in Geneva, Switzerland, with a U.S. research presence in Cambridge, Massachusetts, the company focuses on targeting metabotropic glutamate (mGlu) receptors and GABAB receptors to address unmet medical needs in neurology and psychiatry.

The company’s lead candidate, dipraglurant (ADX48621), is an mGlu5 negative allosteric modulator in clinical development for levodopa-induced dyskinesia in Parkinson’s disease.